CDRH Science Office Details Near-Term Research Priorities
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center is delving further into the underlying science of stents, biomarkers and magnetic resonance imaging according to its three-year research plan
You may also be interested in...
Imaging Is Key To Product Development In Critical Path Opportunities List
Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative
CDRH Science Office Will Team With Industry On Internal Research Agenda
CDRH's Office of Science & Engineering Laboratories will consult with industry and academia experts in a fall evaluation of device research projects, according to Director Larry Kessler
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.